Table 3.

Lifetime Costs and Outcomes of Alternative Strategie

Strategy*	Discounted Life Expectancy (mo)	Discounted Lifetime Cost ($)	Percent Utilizing 3rd Line HAART	Rate of ODs (per 100 PY) **	Incremental Cost-Effectiveness Ratio ($/yr of life gained)
CD4 counts only available
A	78.7	6,299	NA	11.7	–
B	76.1	6,892	18.1	12.8	Dominated†
C	79.3	6,423	6.5	10.9	2,581
Viral loads available
A	81.0	7,645	NA	10.9	-
B	81.1	8,006	30.3	11.3	Dominated by extended dominance‡
C	82.6	8,526	25.6	9.7	6,519

^*The letter refers to the strategies listed in Table 1 (A, 2 regimens; B, 3 regimens with triple NRTI as initial therapy; and C, 3 regimens with second generation PI).

^**ODs – opportunistic diseases.

^†/‡Dominated strategies had at least one other strategy that was more effective and less costly than the dominated strategy. Extended dominance means that some blend of two strategies was more effective and less costly than the dominated strategy.